Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors

NCT04099277 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04099277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04099277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Terminated
Start date
October 28, 2019
Completion date
March 5, 2020
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cervical carcinoma, gastric adenocarcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, high grade serous ovarian carcinoma, leiomyosarcoma, solid tumor, triple-negative breast cancer, undifferentiated pleomorphic sarcoma